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Abstract
Background: Physical and psychological symptoms are the hallmark of patients’ subjective perception of their
illness. The purpose of this analysis was to determine if patients with COPD have distinctive symptom profiles and
to examine the association of symptom profiles with systemic biomarkers of inflammation.
Methods: We conducted latent class analyses of three physical (dyspnea, fatigue, and pain) and two psychological
symptoms (depression and anxiety) in 302 patients with moderate to severe COPD using baseline data from a
longitudinal observational study of depression in COPD. Systemic inflammatory markers included IL1, IL8, IL10, IL12,
IL13, INF, GM-CSF, TNF-α (levels >75thcentile was considered high); and CRP (levels >3 mg/L was considered high).
Multinominal logistic regression models were used to examine the association between symptom classes and
inflammation while adjusting for key socio-demographic and disease characteristics.
Results: We found that a 4-class model best fit the data: 1) low physical and psychological symptoms (26%,
Low-Phys/Low-Psych), 2) low physical but moderate psychological symptoms (18%, Low-Phys/Mod Psych), 3)
high physical but moderate psychological symptoms (25%, High-Phys/Mod Psych), and 4) high physical and
psychological symptoms (30%, High-Phys/High Psych). Unadjusted analyses showed associations between
symptom class with high levels of IL7, IL-8 (p ≤ .10) and CRP (p < .01). In the adjusted model, those with a
high CRP level were less likely to be in the High-Phys/Mod-Psych class compared to the Low-Phys/Low-Psych
(OR: 0.41, 95%CI 0.19, 0.90) and Low-Phys/Mod-Psych classes (OR: 0.35, 95%CI 0.16, 0.78); elevated CRP was
associated with in increased odds of being in the High-Phys/High-Psych compared to the High-Phys/Mod-Psych
class (OR: 2.22, 95%CI 1.08, 4.58). Younger age, having at least a college education, oxygen use and depression
history were more prominent predictors of membership in the higher symptom classes.
Conclusions: Patients with COPD can be classified into four distinct symptom classes based on five commonly
co-occurring physical and psychological symptoms. Systemic biomarkers of inflammation were not associated
with symptom class. Additional work to test the reliability of these symptom classes, their biological drivers and
their validity for prognostication and tailoring therapy in larger and more diverse samples is needed.
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Background
Symptoms are the hallmark of patients’ experience of ill-
ness and their responses to it, and patients with chronic
obstructive pulmonary disease (COPD) experience a high
burden of symptoms such as dyspnea, fatigue, anxiety and
depression. COPD is a heterogeneous disease [1, 2] with
patients experiencing different patterns of common symp-
toms [3, 4]. In a recent study, Park and Larson [3] found
that COPD patients tended to cluster in either two or
three groups based on the overall burden of dyspnea, fa-
tigue, depression and anxiety, and that symptom clusters
had a stronger association with mortality than individual
symptoms. Recent evidence also suggests that pain is an
additional symptom that contributes to the overall symp-
tom burden in COPD that has not previously been well-
recognized [5].
Understanding the biological mechanisms that under-
lie the inter-individual variability in patients’ symptom
experiences could help inform future treatment ap-
proaches. Previous research suggests that differences in
symptom experiences may be due to an individual’s ability
to respond to physical and psychological stressors through
changes in pro- and anti-inflammatory cytokines. Admin-
istration of inflammatory agents has been shown to induce
“sickness behaviors” with subjects reporting fatigue, de-
pression, anxiety, sleepiness, and hyperalgesia [6, 7] The
majority of studies to date in COPD have focused on the
association between depressive symptoms and selected
pro-inflammatory markers with some studies showing a
positive relationship [8, 9], whereas others did not [10–13]
Very little is known regarding the relationship between
markers of systemic inflammation and common co-
occurring COPD symptoms such as dyspnea, fatigue, pain,
depression, and anxiety.
Therefore, the first aim of this paper were to deter-
mine if patients with stable COPD can be classified into
distinct symptom classes based on the severity of their
physical (dyspnea, fatigue and pain) and psychological
symptoms (depression and anxiety). The second aim was
to determine the association between these symptom
classes and systemic biomarkers of inflammation.
Methods
Study design/settings
The COPD Activity: Serotonin Transporter, Cytokines
and Depression (CASCADE) cohort is a multi-site pro-
spective observational study of COPD patients who were
followed for 2 years to study the biological causes and
functional consequences of depression. This manuscript
is a cross-sectional descriptive analysis of data from 302
patients collected at entry to CASCADE. This study was
approved by the respective institutional review boards at
three clinical sites: University of Washington, Seattle
(37332), VA Puget Sound Health Care System (00240),
and University of Texas Health Science Center at San
Antonio/South Texas Veterans Health Care System
(HSC20100373H) and was registered with Clinical-
Trials.gov (NCT01074515).
Participants
We recruited patients from queries of medical records
and pulmonary function tests, chest clinics from the three
medical centers, a research database maintained by the
investigators, pulmonary rehabilitation programs, better
breathers groups, community pulmonary practices, adver-
tisements, study web site, and other referrals. The
inclusion criteria were: 1) Clinical diagnosis of COPD 2)
Post-bronchodilator forced expiratory volume in one sec-
ond to forced vital capacity ratio (FEV1/FVC) < 70%; 3)
Moderate to very severe disease with an FEV1 < 80%; 4)
Age > 40 years; and 5) Current or past cigarette smoking
(>10 pack-years); 6) Stable disease with no acute exacerba-
tions of COPD in the past 4 weeks; 7) Ability to speak,
read and write English. Because this study was focused
on COPD-related inflammation we excluded patients
who reported any of the following conditions: other
chronic lung diseases (e.g. asthma, bronchiectasis, cystic
fibrosis, or idiopathic pulmonary fibrosis), uncompensated
heart failure (exacerbation in the past 4 weeks), primary
pulmonary vascular disease, chronic antibiotic use or
ongoing infection, autoimmune disease, lung cancer or
metastatic cancer, chronic renal failure requiring dialysis,
chronic uncompensated liver disease, HIV/AIDS, or
chronic oral prednisone use. As this study was focused on
depression, we also excluded those with bipolar disease,
psychotic disorders, and dementia.
Procedures
Informed consent was obtained prior to clinic assess-
ments, which included pre- and post-bronchodilator
spirometry performed according to American Thoracic
Society standards using an EasyOne spirometer (ndd
Medical Technologies Inc, Andover, MA) and completion
of questionnaires and a six minute walk test. Two days
after this clinic visit, a depression and anxiety assessment
was completed via telephone by a trained mental health
professional.
Measures
Demographic data included self-reported age, gender,
education, income, living situation, marital status, and
smoking status.
Disease severity included distance covered on a six mi-
nute walk test, body mass index, self-report of chronic
conditions (Charlson co-morbidity index), oxygen supple-
mentation, and post bronchodilator FEV1.
History of Depression was measured using the Structured
Clinical Interview for Depression (SCID) [14] Any score
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other than zero on the SCID (indicating at least one epi-
sode of depression during a participant’s lifetime, excluding
the current episode of depression if any) was considered to
be positive. The age of when the first episode occurred was
also captured.
Dyspnea was measured with the Shortness of Breath
Questionnaire (SOBQ) [15] Fatigue was measured with
the Chronic Respiratory Questionnaire (CRQ-Fatigue
subscale) [16] Pain was measured with the pain subscale
of the Medical Outcomes Study Short-Form 36 [17]
Depression and Anxiety were measured with the Hospital
Anxiety and Depression Scale [18].
Markers of Systemic Inflammation included high sensi-
tivity C-reactive protein (CRP), and a panel of inflamma-
tory cytokines: Interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-10, IL12, IL13, Interferon (INF), Granulocyte
macrophage-colony stimulating factor (GM-CSF), and
Tumor necrosis factor (TNF-α). These markers were se-
lected because they were either related to COPD severity
or depression based on the published literature [19].
Peripheral blood was collected by venipuncture into
vacutainer tubes with ethylenediaminetetraacetic acid
anticoagulant. Blood was collected between 9:30 AM and
4:00 PM at each in-clinic assessment. Plasma was obtained
by centrifugation of tubes at 2000 X g for 10 min. The
samples were stored at -70 0C until analyzed. The concen-
trations of CRP were measured using a duoset ELISA
(R&D Systems); the lower limit of detection was 15.5 pg/
mL. The remaining cytokines were measured using the
Luminex multiplex platform with Millipore Milliplex High
Sensitivity Human Cytokine Magnetic Beads. The lower
limit of detection was 0.13 pg/mL. A cut off of >3 mg/L
was used to classify patients as having high levels of
CRP; for the remaining inflammatory markers, values
greater than the 75th percentile was considered high
levels of inflammation.
Data analysis
We conducted latent class/profile analyses [20] of three
physical symptoms (dyspnea, fatigue, and pain) and two
psychological symptoms (depression and anxiety) to
identify distinct classes (subgroups) of symptom pro-
files. Patients were assigned a probability of being in
each of the identified classes with the goal of creating a
model that uniquely assigned a subject to a given class
(e.g. Pr(ClassA) = 1.0; Pr(ClassB) = 0.0), or at minimum,
provided a distinctively high probability to a given class
versus all others (e.g. .95 versus .05). Model fit was eval-
uated using information criteria fit indices (Bayesian Infor-
mation Criterion, BIC and Akaike’s Information Criterion,
AIC); low values indicate model parsimony. We also used
other criteria to identify a meaningful fit of model and
data and these included class interpretability (the extent
to which additional classes provided unique information),
class prevalence (preferring classes with at least 2% of the
sample for improved replicability), and entropy (a measure
of classification based on posterior probability values, with
higher values representing better classification). We used
analysis of variance and Chi square tests to examine un-
adjusted differences in socio-demographic characteristics,
disease severity, and inflammatory markers across the four
classes. Covariates from unadjusted models were included
in the final adjusted multinomial logistic regression model
if they contributed substantially to model fit, were consid-
ered clinically important, or in the case of inflammatory
markers, those with a p value <0.10. We used MPlus
(version 5.0, Los Angeles, CA) for the latent profile
analyses and STATA (version 14, College Station, TX) for




Two-, three-, four-, and five-class solutions were tested
as possible fits to the data. Overall, the statistical criteria
for model fit (Bayesian and Akaike’s) and classification
(entropy) combined with clinical relevance suggested
that the four-class solution provided the best representa-
tion of the data (BIC = 6026, AIC = 6002, and entropy =
0.87). In the four-class solution, the first class included
patients with the lowest burden of physical and psycho-
logical symptoms (26%, “Low-Phys/Low-Psych”), the
second included patients with low physical but moderate
psychological symptoms (18%, “Low-Phys/Mod-Psych”),
the third included patients with high physical and
moderate psychological symptoms (25%, “High-Phys/
Mod-Psych”), and the fourth included patients with
the worst physical and psychological symptoms (30%,
“High-Phys/High-Psych”). The mean raw values and
standardized z-scores for dyspnea, fatigue, pain, anx-
iety and depression across the four symptom classes
are shown in Table 1 and Fig. 1, respectively.
Unadjusted associations between symptom class
membership and inflammatory markers
Unadjusted differences in socio-demographic characteris-
tics, disease severity, and inflammatory markers across the
four symptom classes are shown in Tables 1 and 2. The
higher symptom classes tended to have younger patients,
a greater proportion of women and those with lower
income (all, p < 0.05) In terms of disease severity, the six
minute walk test distance was lower and oxygen use was
more common in the higher symptom classes whereas
there was no difference in FEV1 % predicted, BMI or
number of comorbidities across the four symptom classes.
Patients who had their first depression episode before
40 years of age were more likely to be in the highest symp-
tom class. As for the inflammatory markers, 18–36% of
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patients had cytokine levels greater than the 75th percent-
ile across symptom classes and for CRP, a higher percent-
age (31–60%) had levels greater than 3 mg/L. Only CRP
(p = .005) was different across groups, followed marginally
by IL-7 (p = .08) or IL-8 (p = .10).
Adjusted associations between symptom class
membership and inflammatory markers
Results of the multinomial adjusted logistic regression
analyses are shown in Table 3. Only CRP was signifi-
cantly associated with symptom class, where patients
with a high CRP level were less likely to be in the High-
Phys/Mod-Psych class compared to both the Low-Phys/
Low-Psych (OR: 0.41, 95%CI 0.19, 0.90) and Low-Phys/
Mod-Psych classes (OR: 0.35, 95%CI 0.16, 0.78); interest-
ingly, elevated CRP was associated with in increased
odds of being in the High-Phys/High-Psych symptom
class compared to the High-Phys/Mod-Psych class (OR:
2.22, 95% CI 1.08, 4.58).
We found that several socio-demographic and disease
severity characteristics were associated with symptom
class. In general, older age was associated with a lower
risk of being in the higher symptom classes compared to
younger age (OR: 0.87 to 0.94). Having a college educa-
tion was associated with a two to four fold odds of being
in a higher symptom class compared to those with lower
Table 1 Socio-demographic characteristics and disease severity across four symptom classes









Variables n = 302 (n = 80) (n = 55) (n = 77) (n = 90)
Socio-Demographics
Age, years 68 ± 9 72 ± 9 68 ± 8 68 ± 8 64 ± 8 <.001‡†§°∞
Females 59 (20%) 8 (10%) 10 (18%) 16 (21%) 25 (28%) .04§
Education, some college+ 234 (77%) 54 (68%) 48 (87%) 62 (81%) 70 (78%) .05
Income, > $20,000/year 184 (62%) 22 (29%) 16 (29%) 34 (44%) 43 (48%) .02
Live with others 223 (74%) 61 (76%) 39 (71%) 57 (74%) 66 (73%) .92
Currently smoking 86 (28%) 17 (21%) 19 (35%) 24 (31%) 26 (29%) .35
Disease Severity/Burden
6-min walk test (feet) 1085 ± 371 1136 ± 370 1196 ± 310 984 ± 344 1061 ± 407 .005∫
FEV1% predicted 45.0 ± 15.8 48.1 ± 18.0 45.3 ± 14.6 42.0 ± 13.3 44.4 ± 16.2 .12
O2 supplementation 100 (33%) 18 (23%) 11 (20%) 33 (43%) 38 (42%) .002†§∫°
Number of co-morbidities .39
0 139 (46%) 37 (46%) 27 (49%) 30 (39%) 45 (50%)
1 96 (32%) 30 (38%) 14 (25%) 25 (32%) 27 (30%)
2 or more 67 (22%) 13 (16%) 14 (25%) 22 (29%) 18 (20%)
Body mass index (BMI) 28.2 ± 6.1 27.8 ± 4.8 27.3 ± 5.1 29.5 ± 6.5 27.9 ± 7.1 .15
Physical Symptoms
Dyspnea, SOBQ (↓0–120) 42.4 ± 22.7 30.8 ± 18.2 22.1 ± 11.7 58.4 ± 16.8 51.5 ± 21.3 <.001‡†§∫°
Fatigue, CRQ (4–28↑) 15.8 ± 4.8 20.0 ± 3.6 19.2 ± 2.7 13.2 ± 3.1 12.3 ± 3.7 <.001†§∫°
Pain, SF-36 (0–100↑) 61.8 ± 24.3 74.2 ± 22.1 75.3 ± 22.7 52.1 ± 19.4 50.8 ± 21.7 <.001†§∫°
Psychological Symptoms
Anxiety, HAD-A (↓0–21) 5.0 ± 3.9 1.5 ± 1.3 4.7 ± 2.5 4.3 ± 2.6 8.9 ± 3.6 <.001‡†§°∞
Depression, HAD-D (↓0–21) 4.2 ± 4.1 0.3 ± 0.5 3.2 ± 2.0 2.9 ± 1.7 9.4 ± 2.8 <.001‡†§°∞
Depression history <.001†§
None 101 (33%) 45 (56%) 19 (35%) 23 (30%) 14 (16%)
First episode < = 40 y/o 137 (45%) 23 (29%) 25 (45%) 35 (45%) 54 (60%)
First episode > 40 y/o 64 (21%) 12 (15%) 11 (20%) 19 (25%) 22 (24%)
Values are presented as mean ± SD or n(%); Phys = Physical Symptoms; Psych = Psychological Symptoms; Mod: Moderate. SOBQ = Shortness of Breath
Questionnaire; CRQ = Chronic Respiratory Questionnaire; SF-36 = Short Form Health Survey Pain Scale; HAD-D = Hospital Anxiety & Depression Scale; HAD-A = Hos-
pital Anxiety & Depression Scale; score ranges with arrows indicating direction of better scores. Post-hoc pairwise contrasts, p < .05: ‡Class1 vs. Class2, †Class 1 vs.
Class 3, §Class 1 vs. Class 4, ∫Class 2 vs. Class 3, °Class 2 vs. Class 4, ∞Class 3 vs. Class 4
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symptom levels (OR: 2.71 to 4.33). Oxygen use was associ-
ated with higher odds of membership in the High-Phys/
High-Psych compared to both the Low-Phys/Low-Psych
(OR: 3.18, 95%CI 1.21, 8.36) and the Low-Phys/Mod-Psych
(OR: 3.41, 95%CI 1.29, 9.01) symptom classes. Patients
with a depression history had two to six times the odds
of being in the High-Phys/Mod-Psych or High-Phys/
High-Psych symptom classes compared to being in the
Low-Phys/Low-Psych or Low-Phys/Mod-Psych classes
(OR: 2.66 to 6.55). Gender, living situation, smoking sta-
tus, six minute walk test performance, FEV1% predicted,
BMI, or number of co-morbidities did not distinguish
across the four symptom classes.
Discussion
We identified four distinct symptom classes based on
three common physical (dyspnea, fatigue, and pain) and
two psychological (depression and anxiety) symptoms in a
sample of patients with COPD: 1) low physical and psy-
chological symptoms (26%), 2) low physical but moderate
psychological symptoms (18%), 3) high physical but mod-
erate psychological symptoms (25%), and 4) high physical
and psychological symptoms (30%). Systemic inflamma-
tion as measured by 14 serum biomarkers did not appear
to have any consistent relationship with these empirically
identified symptom classes with the exception of CRP.
Another notable finding was that younger age and depres-
sion history were associated with higher odds of member-
ship in the higher symptom classes.
Our study differs from two previous reports using data
from ~600 participants randomized to the control group
of the National Emphysema Treatment Trial (NETT).
Those studies used a hierarchical clustering approach and
identified two or three symptom subgroups compared to
the four classes we identified [3, 4]. Patients enrolled in
NETT all had very severe COPD with air-trapping and
few comorbidities, and therefore differ from our study
Fig. 1 Pattern of COPD symptom classes based on normalized
symptom scores. *Z-scores on Y-axis; higher z-scores indicate worse
symptoms. Class 1 (diamond): Low physical and low psychological
symptom burden (Low-Phys/Low-Psych); 26%. Class 2 (square): Low
physical and moderate psychological symptom burden (Low-Phys/
Mod-Psych); 18%. Class 3 (triangle): High physical and moderate
psychological symptom burden (High-Phys/Mod-Psych); 25%. Class 4
(circle): High physical and high psychological symptom burden
(High-Phys/High-Psych); 30%
Table 2 Inflammatory markers across four symptom classes















Variables n = 302 (n = 80) (n = 55) (n = 77) (n = 90)
Interleukin-1 (IL-1), pg/mL 0.6 (0.2,1.5) 18 (23%) 16 (29%) 19 (25%) 25 (28%) 0.80
Interleukin-2 (IL-2), pg/mL 2.7 (1.0,7.1) 18 (23%) 18 (33%) 20 (26%) 22 (24%) 0.59
Interleukin-4 (IL-4), pg/mL 17.3 (7.1, 42.3) 22 (28%) 15 (27%) 16 (21%) 25 (28%) 0.71
Interleukin-5 (IL-5), pg/mL 0.9 (0.4,1.9) 20 (25%) 13 (24%) 18 (23%) 26 (29%) 0.84
Interleukin-6 (IL-6), pg/mL 2.9 (1.8, 5.0) 22 (28%) 16 (29%) 23 (30%) 16 (18%) 0.25
Interleukin-7 (IL-7), pg/mL 2.4 (1.1, 4.7) 29 (36%) 12 (22%) 17 (22%) 19 (21%) 0.08
Interleuken-8 (IL-8), pg/mL 3.7 (2.7, 5.7) 27 (34%) 17 (31%) 17 (22%) 17 (19%) 0.10
Interleukin-10 (IL-10), pg/mL 18.3 (10.5, 37.4) 24 (30%) 14 (25%) 18 (23%) 21 (23%) 0.74
Interleukin-12 (IL-12), pg/mL 3.9 (1.8, 8.4) 22 (28%) 17 (31%) 15 (19%) 23 (26%) 0.48
Interleukin-13 (IL-13), pg/mL 0.5 (0.1, 3.9) 20 (25%) 18 (33%) 20 (26%) 20 (22%) 0.57
Interferon (IFN), pg/mL 9.2 (4.1, 21.0) 19 (24%) 17 (31%) 16 (21%) 25 (28%) 0.55
Granulocyte macrophage-colony stimulating
factor (GM-CSF), pg/mL
2.8 (1.3, 6.9) 20 (25%) 17 (31%) 17 (22%) 23 (26%) 0.72
Tumor necrosis factor
(TNF-α), pg/mL
4.7 (3.3, 6.8) 25 (31%) 14 (25%) 21 (27%) 17 (19%) 0.31
High sensitivity C-reactive protein (CRP), mg/L 3.2 (1.5, 6.0) 42 (52%) 33 (60%) 23 (31%) 43 (48%) 0.005†∫∞
Values for the total sample are presented as median (IQR); by symptom class, n (%) > 75th percentile or % of patients with CRP > 3 mg/L. Phys = Physical
Symptoms; Psych = Psychological Symptoms; Mod: Moderate. Post-hoc pairwise contrasts, p < .05: †Class 1 vs. Class 3, ∫Class 2 vs. Class 3, ∞Class 3 vs. Class 4
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Odds Ratio (95%CI) Odds Ratio (95%CI) Odds Ratio (95%CI) Odds Ratio (95%CI) Odds Ratio (95%CI) Odds Ratio (95%CI)
Socio-Demographics
Age, years 0.94* (0.89–0.99) 0.94* (0.89–0.99) 0.87*** (0.83–0.92) 1.00 (0.94–1.05) 0.93** (0.88–0.98) 0.93** (0.89–0.98)
Females 1.73 (0.56–5.33) 1.89 (0.65–5.50) 1.99 (0.70–5.66) 1.09 (0.42–2.85) 1.15 (0.46–2.89) 1.06 (0.48–2.32)
Education, some
college+
4.33** (1.57–11.9) 3.63** (1.46–9.00) 2.71* (1.10–6.69) 0.84 (0.29–2.44) 0.63 (0.22–1.79) 0.75 (0.32–1.74)
Income, > $20,000/year 0.96 (0.41–2.25) 0.65 (0.29–1.46) 0.63 (0.28–1.41) 0.68 (0.30–1.53) 0.66 (0.30–1.46) 0.97 (0.49–1.94)
Currently smoking 1.31 (0.50–3.44) 1.37 (0.53–3.56) 0.89 (0.35–2.27) 1.05 (0.43–2.58) 0.68 (0.28–1.63) 0.65 (0.29–1.43)
Disease Severity/Burden
6-min walk test (for
every 100 feet change)
1.00 (0.88–1.14) 0.91 (0.81–1.03) 0.91 (0.80–1.02) 0.91 (0.81–1.03) 0.91 (0.81–1.02) 0.99 (0.90–1.10)
FEV1% predicted 0.99 (0.96–1.02) 0.99 (0.96–1.01) 1.01 (0.98–1.04) 1.00 (0.97–1.03) 1.02 (1.00–1.05) 1.03*(1.00–1.05)
O2 supplementation 0.93 (0.33–2.63 2.02 (0.81–5.05) 3.18*(1.21–8.36) 2.16 (0.84–5.59) 3.41* (1.29–9.01) 1.58 (0.71–3.51)
Number of co-morbidities
0 Reference Reference Reference Reference Reference Reference
1 0.84 (0.35–2.05) 1.42 (0.60–3.33) 1.16 (0.49–2.71) 1.68 (0.68–4.16) 1.37 (0.56–1.33) 0.82 (0.38–1.78)
2 or more 2.14 (0.75–6.14) 2.76 (0.97–7.85) 1.91 (0.65–5.62) 1.29 (0.48–3.44) 0.89 (0.33–2.40) 0.69 (0.28–1.69)
Body mass index 1.01 (0.93–1.09) 1.05 (0.98–1.13) 1.01 (0.94–1.08) 1.04 (0.97–1.12) 1.00 (0.93–1.07) 0.96 (0.91–1.02)
Depression history
None Reference Reference Reference Reference Reference Reference
First episode < = 40 y/o 1.70 (0.70–4.12) 2.66* (1.10–6.41) 6.31*** (2.49–16.0) 1.56 (0.63–3.90) 3.71** (1.41–9.71) 2.37 (0.99–5.69)
First episode > 40 y/o 1.61 (0.57–4.59) 3.11*(1.15–8.45) 6.55*** (2.27–18.9) 1.93 (0.68–5.49) 4.07* (1.36–12.2) 2.10 (0.79–5.59)
IL-7 pg/ml > 75th
centile
0.61 (0.23–1.59) 0.62 (0.24–1.55) 0.81 (0.33–2.04) 1.01 (0.37–2.78) 1.33 (0.50–3.58) 1.32 (0.55–3.17)
IL-8 pg/ml > 75th
centile
0.81 (0.33–1.96) 0.42 (0.17–1.04) 0.36* (0.14–0.89) 0.52 (0.20–1.32) 0.44 (0.18–1.10) 0.85 (0.35–2.04)
hsCRP > 3 mg/dl 1.18 (0.53–2.59) 0.41*(0.19–0.90) 0.92 (0.42–1.99) 0.35*(0.16–0.78) 0.78 (0.36–1.70) 2.22*(1.08–4.58)
Phys physical, Psych psychological, Mod moderate















sample. Another difference was that we used pain as a
fifth measure of symptom burden, and although pain is
not traditionally thought of as a COPD-related symp-
tom, a recent large observational study found that pain
and dyspnea are often inter-related [5]. In addition, al-
though we found that patients tended to have either
high or low physical symptom burden, psychological
burden tended to be grouped into low (essentially no
psychological symptoms), moderate (some psychological
symptoms) and high (psychological symptoms that are in
the range of clinically meaningful depressive and anxiety
symptoms). The observation of a distinct class of patients
who have high physical but only moderate levels of psy-
chological symptoms challenge the common notion that
physical and psychological symptoms are tightly coupled
in patients with COPD [21] Confirmation of such a symp-
tom cluster in other COPD cohorts is needed.
Contrary to our hypothesis, we did not find that mea-
sures of systemic inflammation were associated with
membership in symptom classes with the exception of
CRP. The relationships between CRP and symptom class
were however, not always consistent. Elevated CRP levels
were associated with a lower odds of belonging to the
High-Phys/Mod-Psych class compared to the Low-Phys/
Low-Psych or Low-Phys/Mod-Psych class yet the odds
of being in the High-Phys/High-Psych class compared to
the High-Phys/Mod-Psych class were greater for those
with higher CRP. Although COPD is associated with in-
creased systemic inflammation compared to not having
COPD, there is evidence that patients with severe COPD
and frequent exacerbations experience immune down-
regulation due to chronic stimulation of the immune sys-
tem [22, 23]. This could explain the paradoxical effects of
lower CRP levels in patients with only high physical symp-
toms and moderate psychological symptoms. In contrast,
the mechanisms underlying the elevated CRP levels for
patients with both high physical and psychological symp-
toms may be quite different. It is possible that in these pa-
tients, high psychological symptom burden precedes and
exaggerates the perception of physical symptoms partly
through a somatization pathway that is not tightly linked
to the severity of COPD per se [24].
The finding from the ECLIPSE study that not all pa-
tients with COPD have elevated systemic markers of in-
flammation partly corroborates our null findings between
symptom severity and nearly all the measured biomarkers;
in fact, only 16% of the ECLIPSE cohort of over two thou-
sand patients had persistent inflammation and one third
never showed evidence of systemic inflammation as mea-
sured with 34 biomarkers after a year of follow up [25].
Several early studies in both COPD and other clinical
populations reported that higher levels of inflammatory
markers were associated with worse fatigue and depres-
sion [9, 26–28] In contrast, more recent studies found no
relationship between systemic inflammation and depres-
sion with authors concluding that patients’ symptom
experience is likely driven more by other factors, e.g.
perception of disability and underlying psychiatric history,
rather than physiological changes [10–13]. It is possible
that the underlying biological relationship between phys-
ical and psychological symptoms and circulating cytokines
is far more complex than we were able to appreciate with
our analyses and that the significant associations with only
CRP could be spurious.
Our finding showing that younger age and depression
history but not gender were predictive of membership
in the High-Phys/High-Psych class deserves further
comment. It is important to note that our assessment
of depression history only includes previous episodes,
not any current depression. A significantly higher num-
ber of patients in this class experienced their first de-
pression episode during the first three decades of life
compared to the other classes. Thus, younger age may
be a reflection of an early and persistent psychiatric his-
tory in this subgroup of patients who experience more
severe physical symptoms despite similar levels of air-
flow obstruction. Moreover, previous studies show that
patients with a lifetime history of depression are twice
as likely to smoke compared to someone without such
a history [29] and have greater difficulty with smoking
cessation, not engage in self-care, [30] and thus, experi-
ence a worse disease trajectory. Interestingly, we did
not find a difference in smoking exposure, at least
based on the self-reported number of years patients
smoked in this sample. In contrast to previous studies,
[31, 32] we did not find that women were more likely
to experience worse physical and psychological symp-
toms compared to men. The absence of a gender effect
on symptom class may be due to insufficient power
with a smaller number of women (20%) in this sample.
However, it is plausible that after simultaneously adjust-
ing for other relevant variables as we had done, espe-
cially depression history, that women with COPD are
no more likely to report worse physical and psycho-
logical symptoms compared to men.
Limitations
Although we applied a state-of-the-art analytical tech-
nique to characterize latent symptom classes, there is
some subjectivity to identifying how many classes are
sufficient; confidence in the final class solution was
based on a combination of statistical indices of fit, the
clinical meaningfulness and conceptual interpretability
of the class structure [20]. This was a cross-sectional
study thus assessing the temporal stability of the identi-
fied symptom classes and whether baseline antecedent
variables remain predictive of membership in these
classes will be important in future studies. Replication
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of these symptom classes should be confirmed in other
larger COPD samples with less restrictive inclusion cri-
teria such as ours where patients were excluded if they re-
ported a known disorder with an underlying inflammatory
mechanism. While the high sensitivity assays can measure
circulating cytokines at very low levels, the clinical rele-
vance of these very low levels could be questioned. Finally,
we did not include the breadth of symptoms that patients
with COPD experience; however, the five symptoms we
did include captures the most prevalent and distressing
symptoms for this population [33].
Conclusions
Use of a universal patient reported outcome metric such
as symptoms to risk-stratify individuals is increasingly im-
portant when nearly two thirds of older adult patients
have multi-morbidities and disease specific-metrics alone
are insufficient to represent the heterogeneity within spe-
cific clinical populations [34]. We were able to identify four
distinct symptom classes (low physical/psychological, low
physical/moderate psychological, high physical/moderate
psychological, and high physical/psychological) based on
five common symptoms in this sample of patients with
stable COPD. Overall, we did not find any consistent asso-
ciation between the 14 serum biomarkers of systemic in-
flammation with symptom severity. While additional work
is needed to test the reliability of these symptom classes,
their biological drivers and their validity for prognostica-
tion and tailoring therapy in larger samples in longitudinal
studies, there is clearly a subgroup of young COPD pa-
tients with a long standing depression history who need
more intensive and integrative management of both their
mental and physical health.
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